Levi Strauss shorts rebuild ahead of Tuesday earnings

Options positioning has eased from its most defensive readings. The put/call ratio is 1.52, still elevated in absolute terms but a full 1.3 standard deviations below its 20-day average of 1.60. That is a meaningful shift: the PCR was running above 1.70 through late August and has been compressing steadily. That compression, while the stock has continued to fall, suggests options hedgers are no longer pressing new downside protection at the rate they were. The 52-week low on the PCR is 0.37, and at 1.52 the market remains structurally cautious, just less so than a month ago.

The Street is broadly constructive but losing conviction on valuation. Most analysts hold buy-equivalent ratings with targets in the mid-to-upper $20s. JP Morgan carried an Overweight with a $34 target as recently as early August. Citigroup moved today, cutting its target from $25 to $22 while holding Neutral. That is a notable signal from a bellwether firm less than a week before the print: not a downgrade, but a reset of what fair value looks like given the macro backdrop. The mean target across the panel sits near $28, implying roughly 40% upside to the current price, though targets above $30 risk looking stale as the stock has drifted lower. The EV/EBITDA multiple is 8.2x, down modestly over the past month. PE is 11.9x, also compressing. On the factor side, the dividend score ranks in the 94th percentile, reflecting a high yield relative to history, though the dividend data itself is dated to 2022, which limits that reading. The short score factor ranks in the 25th percentile, flagging that bearish positioning is a meaningful headwind relative to peers.

The bull case rests on DTC momentum. Bulls point to 17 consecutive quarters of positive direct-to-consumer comparable sales growth, women's revenue up 11%, and a 62.6% gross margin as evidence that brand health is intact. Bears counter that the path to $10 billion in revenue and 15% operating margins remains distant, and that tariff volatility and weaker discretionary spending could pressure the Q4 trajectory even if Q3 holds up. Management has guided to FY26 adjusted EPS of $1.52, rising to $1.70 in FY27, and the earnings print will be scrutinised for any revision to that cadence.

The recent earnings history adds context without offering comfort. The July Q2 print saw the stock fall 3.3% the next day and end the five-day window 3.2% lower. The print before that was essentially flat. Neither reaction was catastrophic, but the stock was trading higher into those events. It is now approaching a lower base with more short interest in place. Peers were broadly weak this week: UAA fell nearly 10%, KTB dropped 5.2%, while RL and ZGN managed modest gains, leaving LEVI's 1.5% weekly decline roughly in the middle of the peer group.

Wikipedia attention for Levi Strauss is running about 1.4 standard deviations above its own 90-day average, suggesting a recent uptick in retail interest. This is a directional attention signal rather than a revenue indicator.

The October 6 print is the next hard catalyst. The key question is whether the DTC comp streak holds and whether management reaffirms its FY27 margin targets in the face of a less cooperative macro environment.